Business
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a
About this update from Dariohealth Corp.
[{"type":"text","content":"New research confirms behavior change driven by Dario digital platform is sustainable for 12 month period and supports clinical results for members taking a GLP-1\nAdditional research demonstrates 31% of Dario members with Type 2 diabetes achieve results reflecting diabetes remission \nNEW YORK, June 25, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (\"Dario\" or the \"Company\"), a leader in the global digital health market, announced today two new studies presented this past weekend at the 84th Annual American Diabetes Association (ADA) Scientific Sessions in Orlando. The first study provides an analysis of member data for those tracking a GLP-1 medication in Dario's cardiometabolic solution.\n\n \nAdopting healthy behaviors while taking a GLP-1 is crucial for the efficacy of the drug. The sustainability of these behaviors is proven to be achievable through the innovative technology behind Dario's cardiometabolic solution and integrated tools for GLP-1 medications. Sustainable behavior change allows users to continue to realize healthy outcomes after offboarding the drug.\n\"This new research shows there is tremendous value in giving people a digital health solution designed for behavior change alongside GLP-1 medications. We are excited to see this early data reinforce what we have seen in general member population: our highly personalized approach to behavior change works,\" said Yifat Hershcovitz, PhD., Vice President of Clinical and Scientific Affairs at Dario.\n\"Standards of care for cardiometabolic health are evolving thanks to new GLP-1 medications, but research, including Dario's newest study, continues to demonstrate the importance of effective behavior change. These medications require the meaningful and sustainable change that Dario delivers for our members and our clients to support full realization of the value of these drugs,\" said Omar Manejwala, M.D., Chief Medical Officer.\nDario Members Sustain Healthy Behaviors for 12 Months Alongside While Taking a GLP-1 \nTo understand how Dario can best support members taking a GLP-1, a retrospective analysis was conducted using data from members using Dario to manage Type 2 diabetes or prediabetes and taking either Metformin, a standard medication prescribed for diabetes, or a GLP-1. Both member groups were tracked for 12 months as they engaged with Dario's dig...